Severe pain has profound physiologic effects on the endocrine system. Serum hormone abnormalities may result and these serve as biomarkers for the presence of severe pain and the need to replace hormones to achieve pain control. Initially severe pain causes a hyperarousal of the hypothalamic-pituitaryadrenal system which results in elevated serum hormone levels such as adrenocorticotropin, cortisol, and pregnenolone. If the severe pain does not abate, however, the system cannot maintain its normal hormone production and serum levels of some hormones may drop below normal range. Some hormones are so critical to pain control that a deficiency may enhance pain and retard healing.
INTRODUCTION
Severe pain has profound physiologic effects on the endocrine system [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Fundamentally, severe pain, whether it be acute or chronic, is a severe stressor that activates the hypothalamicpituitary-adrenal-thyroid-gonadal (HPATG) system, which is the major stress control mechanism of the body [10, [13] [14] [15] [16] . This system is often referred to as an 'axis' since it is a closed system with hormonal feedback or controls within the system [16] [17] [18] . This paper will refer to the 'axis' as the HPATG system. The biologic purpose of this system (see Fig. 1 ) is to produce additional hormones in the thyroid, adrenals and gonads, and secrete them into the serum as these compounds are required by the body for many pain-control functions, including protection and regeneration of injured tissue, immunologic activity, and metabolic controls [13, 16, 17] . Once these extra hormones, such as thyroid, cortisol, or testosterone, enter the serum, they travel throughout the body to target areas, including injured nerves and the central nervous system (CNS) [18, 19] . Although it is known that pain has an effect on neurohormones produced in the brain, insulin produced in the pancreas, and adrenalin produced in the adrenal medulla, there are few studies or reports on these effects [1] [2] [3] [4] [5] , and they will not be covered here. Over the past 50 years, however, there have been numerous reports and studies on pain's physiologic effect on the HPATG system, so this is the focus of this paper [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . It is also cogent to note that the accumulated information and understanding about the effects of pain on the HPATG system is now such that testing and replacement of certain hormones should be a basic foundation of clinical pain treatment.
HORMONE FUNCTIONS IN PAIN CONTROL
Adequate pain control may not be achieved without homeostasis of certain hormones . Hormonal homeostasis is defined here as the maintenance of a hormone within a normal serum range. The critical pain-control hormones that are produced in glands outside the CNS are cortisol, pregnenolone, dehydroepiandrosterone (DHEA), progesterone, testosterone, estrogen, and thyroid (Table 1 ) . Among the primary pain-control functions of these hormones are immune and anti-inflammatory actions, cellular protection, tissue regeneration, glucose control, and modulation of CNS receptors, the blood-brain Fig. 1 Pain stimulation of the hormone system causes adrenal, gonad and thyroid hormone levels to elevate in the serum. If pain remains uncontrolled for a considerable time period, hormonal depletion may occur, and serum levels drop below normal barrier, and nerve conduction ( [19, 33, 37, 42, [49] [50] [51] [52] [53] .
The Releasing Hormones
Pain signals that reach the brain from any injury in the peripheral nervous system activate three releasing hormones in the hypothalamus (Fig. 1 ) [8, 9, 15, 48] . These are corticotropin releasing hormone (CRH), gonadal releasing hormone (GRH), and thyroid releasing hormone (TRH) [8, 9, 12, 48] . These three hormones, in turn, cause the anterior pituitary to release into serum adrenal corticotropin hormone (ACTH), follicle stimulating hormone (FSH), luteinizing hormone (LH), and thyroid stimulating hormone (TSH). The end organs for stimulation are the adrenals, gonads, and thyroid, which release into the serum hormones necessary for pain control including cortisol, pregnenolone, DHEA, testosterone, progesterone, estrogen, triiodothyronine (T 3 ), and thyroxine (T 4 ) ( Table 1 ). Adrenalin and other catecholamines are also released from the adrenal medulla, but it is only partially a result of ACTH stimulation. Serum concentrations of the pituitary and end-organ hormones can now be assayed in commercial Table 3 ) [3, 7, 30, 64] . In other words, it may not be possible to quantitate pain per se, but it is now possible to determine whether pain severity has reached a level that activates the HPATG system [29, 64] . It should be noted that commercial assays for the hypothalamic-releasing hormones (CRH, GRH, TRH) are in the developmental stages, and when available, will provide an even more direct assessment of brain overstimulation because of pain [48] .
The Stimulation Phase
It is important to note that only severe pain will stimulate HPATG to the point that the end organs produce and secrete sufficient hormones to raise serum levels above normal ( Fig. 1 ) [29, 65] . Studies show that patients with mild or intermittent pain, such as in common degenerative arthritis, have normal hormone serum levels [65] . This is an excellent practical point for the pain practitioner, since normal serum hormone levels usually mean that the patient's pain is not in need of therapy with high-risk treatment, such as long-acting opioid drugs or invasive interventions [66] [67] [68] [69] [70] [71] [72] [73] [74] . Put another way, hormone serum levels are excellent biomarkers that help separate severe from mild pain. If end-organ serum hormone levels are above normal, however, enhanced pain-control treatment will be needed [75] . If hormones are below normal levels, it is prudent to replace the hormones and achieve homeostasis before embarking on a therapeutic regimen that has risks, such as opioid-induced endocrine suppression [23, [66] [67] [68] [69] [70] [71] [72] [73] [74] .
The Depletion Phase
If tissues in the hypothalamus, pituitary, adrenals, gonads, or thyroid cannot sustain the demands of severe pain, serum levels of some hormones may drop below normal levels [10, 29, 64] . Based on the clinical experience to date, the most common end-organ hormones to diminish in the serum due to uncontrolled pain are cortisol, pregnenolone, DHEA, and testosterone [29, 30, 75] . It is noted that thyroid depletion occurs, but is quite uncommon according to today's testing technology [21] . Also, some clinicians believe that thyroid depletion should be assessed according to the symptoms rather than current assays for T 3 and T 4 [26] . Once pain is controlled and/or hormones are replaced, serum levels will almost always return to normal. It should be emphasized that only severe pain will stimulate HPATG to the point that the end organs will not produce sufficient hormones to maintain homeostasis [65] .
CORTISOL ABNORMALITIES: THE MOST SERIOUS HORMONE COMPLICATIONS
Chronic cortisol abnormalities, when levels are either too high or too low, over an extended time period are the major hormonal problems in chronic pain patients. Although the prevalence of cortisol abnormalities in chronic pain patients is unknown, excess and deficient cortisol states are starting to be recognized among pain patients [7, 10, 29] . Extended periods of exposure to excess cortisol, often referred to as Cushing's Syndrome, named after Harvey Cushing who first described the clinical signs and symptoms in patients with pituitary tumors, has serious complications [76] [77] [78] [79] [80] [81] [82] . Complications include osteoporosis, hypertension, hyperlipidemia, and mental deficiencies (Table 3) . Until now, many of these complications in pain patients were simply viewed as unrelated, random events. Table 3 lists the complications of hypercortisolemia [84] . The major complications that manifest in pain patients are osteoporosis, joint degeneration, tooth decay, hypertension, hyperlipidemia, obesity, and mental deterioration [76] [77] [78] [79] [80] [81] [82] .
Although the hypercortisol complications listed here are well known, the pain patient may decondition themselves to adequately move or exercise. Consequently, multiple reasons for these complications may develop.
The disease originally described by Cushing was due to pituitary adenomas, which we now know is caused by the constant secretion of ACTH by the pituitary, which raises serum cortisol levels [76] [77] [78] 82] Table 4 ) [71, 75, 84] .
SERUM TESTING AND REPLACEMENT
Due to the two phases, stimulation and depletion, of pain's effect on the HPATG system, practitioners should be prepared for either too high or too low serum hormone levels when they are assayed. Replacement or partial replacement of hydrocortisone, pregnenolone, DHEA, or testosterone is rightfully emerging as a new procedure in pain treatment [75, 81] . The benefits appear numerous. In early reports, less medication, particularly opioids, is required if hormone serum levels are normal prior to their initiation [77] . The author highly recommends that hormone testing and necessary replacement can be done before long-acting opioids and other high-risk measures are instituted.
OPIOID SUPPRESSION OF HORMONES
Opioids, particularly those that are long-acting or delivered by the intrathecal route, may suppress some hormone production [66] [67] [68] [69] [70] [71] [72] [73] [74] . Precise opioid dosages that may produce suppression have not been-and probably cannot be-determined due to individual biologic differences [60, 70] . It is the constancy of sustained-action opioids, however, that produces a 24-h blood and brain concentration that does not allow the HPATG to produce its usual, normal output of hormones [63, 68, 69, 76] . Suppressed levels of [85] description of patients who died of adrenal failure testosterone are the most common problem with opioid administration, but cortisol, pregnenolone, and DHEA may also be suppressed [67, 70] . For reasons that are unclear, the thyroid hormones, T 3 and T 4 , are seldom suppressed [25, 70] . The predilection for testosterone suppression is believed to be due to the tendency of opioids to preferentially suppress GRH [72] . Testosterone suppression with long-acting and intrathecal opioids occurs in 75-85 % of patients [66, 70, 72, 74] .
Suppression may begin in the first 90 days of opioid administration and testosterone may remain suppressed as long as opioids are administered. Given this extremely high prevalence, patients who take long-acting opioids need to be regularly screened for testosterone, as well as pregnenolone, DHEA, and cortisol. Replacement of these hormones should be done, as low serum levels of any of these hormones may be associated with poor pain control, including symptoms of allodynia and hyperalgesia [84, 85] . It is known that central sensitization and neuroinflammation due to glial cell activation are responsible for allodynia and hyperalgesia. Some hormones, particularly the glucocorticoids and sex hormones, have profound immune effects on the CNS [39, 41, 49, 54] . Hormone replacement has been reported to relieve allodynia and hyperalgesia in some patients [75, 84] . In a patient who takes opioids, a low serum hormone concentration may be due to opioids, pain, or both. Consequently, in clinical practice, hormone replacement may have to be performed without knowing precisely which mechanism is primarily responsible for hormone deficiencies. 
